{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T20:55:11Z","timestamp":1770497711727,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>The aim of this study was to evaluate the role of cutaneous application of 0.1% tacrolimus eye ointment over the skin of the upper eyelid in chronic vernal keratoconjunctivitis (VKC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A prospective, longitudinal, noncomparative, open-label clinical study of moderate-to-severe grade steroid-dependent VKC was performed. Study participants were initiated on adjunct therapy of cutaneous application of 0.1% tacrolimus ointment twice daily on the upper eyelid skin. Ocular surface evaluation parameters, meibomian gland imaging, intraocular pressure, visual acuity, and clinical disease severity scoring were performed to assess clinical response at baseline and month 3 of therapy. Tear levels of tacrolimus were measured at month 3 using high-performance liquid chromatography tandem mass spectrometry and correlated with the clinical score.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Palpebral form of VKC was observed in 85% of the cases, with positive family history in 5%, atopy in 7.5%, and keratoconus in 11.25%. Clinical assessment revealed improvement in 97.5% patients with discontinuation of concomitant topical steroids in 64% of patients. There were no changes in visual acuity, intraocular pressure, or ocular surface evaluation after therapy. Tacrolimus was detected in the tears of all our study patients after cutaneous application over the upper eyelid skin, proving its bioavailability with mean tear tacrolimus levels of 6.55 \u00b1 21.43 ng\/mL. Correlation analysis revealed a moderate negative correlation between the clinical score and tacrolimus concentration (Spearman correlation coefficient: \u22120.34, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Cutaneous tacrolimus 0.1% ointment over the upper eyelid skin is an efficacious alternative method of application in treatment of VKC, with no resultant ocular irritation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ico.0000000000003404","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T10:08:56Z","timestamp":1699006136000},"page":"820-827","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Tear Tacrolimus Levels and Clinical Response After Adjunct Therapy With Cutaneous Application of Tacrolimus 0.1% Over Upper Eyelid Skin in Chronic Vernal Keratoconjunctivitis"],"prefix":"10.1097","volume":"43","author":[{"given":"Priyadarshana","family":"Bardoloi","sequence":"first","affiliation":[{"name":"Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3643-4260","authenticated-orcid":false,"given":"Murugesan","family":"Vanathi","sequence":"additional","affiliation":[{"name":"Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[{"name":"Ocular Pharmacology Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moksha","family":"Laxmi","sequence":"additional","affiliation":[{"name":"Ocular Pharmacology Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noopur","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neiwete","family":"Lomi","sequence":"additional","affiliation":[{"name":"Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Tandon","sequence":"additional","affiliation":[{"name":"Cornea and Ocular Surface, Cataract and Refractive Services, Dr. R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11,3]]},"reference":[{"key":"R1-20250723","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40123-013-0019-y","article-title":"Management of vernal keratoconjunctivitis","volume":"2","author":"Leonardi","year":"2013","journal-title":"Ophthalmol Ther"},{"key":"R2-20250723","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R3-20250723","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis: a major review","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R4-20250723","doi-asserted-by":"crossref","first-page":"214","DOI":"10.4103\/ijo.IJO_1263_20","article-title":"Pediatric keratoconus - Current perspectives and clinical challenges","volume":"69","author":"Anitha","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"R5-20250723","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R6-20250723","doi-asserted-by":"crossref","first-page":"36.e1","DOI":"10.1016\/j.jaapos.2018.09.010","article-title":"Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population","volume":"23","author":"Samyukta","year":"2019","journal-title":"J AAPOS"},{"key":"R7-20250723","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0192-0561(96)84506-1","article-title":"Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506","volume":"18","author":"Ezeamuzie","year":"1996","journal-title":"Int J Immunopharmacol"},{"key":"R8-20250723","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5935\/0004-2749.20190026","article-title":"Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis","volume":"82","author":"Muller","year":"2019","journal-title":"Arq Bras Oftalmol"},{"key":"R9-20250723","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s00417-019-04287-1","article-title":"Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis","volume":"257","author":"Liu","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20250723","doi-asserted-by":"crossref","first-page":"154","DOI":"10.5935\/0004-2749.20170038","article-title":"Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial","volume":"80","author":"M\u00fcller","year":"2017","journal-title":"Arq Bras Oftalmol"},{"key":"R11-20250723","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clinical grading of vernal keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R12-20250723","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archopht.1983.01040020385009","article-title":"Schirmer's test: a closer look","volume":"101","author":"Clinch","year":"1983","journal-title":"Arch Ophthalmol"},{"key":"R13-20250723","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1167\/iovs.13-12802","article-title":"Corneal staining characteristics in limited zones compared with whole cornea documentation for the detection of dry eye subtypes","volume":"54","author":"Fenner","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20250723","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/ICO.0000000000000038","article-title":"A review of quality of life measures in dry eye questionnaires","volume":"33","author":"Grubbs","year":"2014","journal-title":"Cornea"},{"key":"R15-20250723","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtos.2019.01.004","article-title":"Review and analysis of grading scales for ocular surface staining","volume":"17","author":"Begley","year":"2019","journal-title":"Ocul Surf"},{"key":"R16-20250723","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1097\/ICO.0b013e3182a7f3e1","article-title":"Evaluation of lipid layer thickness measurement of the tear film as a diagnostic tool for Meibomian gland dysfunction","volume":"32","author":"Finis","year":"2013","journal-title":"Cornea"},{"key":"R17-20250723","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/1120672119885050","article-title":"Risk of intraocular pressure elevation after topical steroids in children and adults: a systematic review","volume":"30","author":"Musleh","year":"2020","journal-title":"Eur J Ophthalmol"},{"key":"R18-20250723","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/0301-4738.119431","article-title":"Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India","volume":"61","author":"Saboo","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"R19-20250723","first-page":"75","article-title":"To study the clinical profile of patients of vernal keratoconjunctivitis in Kashmir Valley","volume":"9","author":"Ramzan","year":"2019","journal-title":"Int J Health Sci Res"},{"key":"R20-20250723","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/ACI.0000000000000765","article-title":"Vernal keratoconjunctivitis and keratoconus","volume":"21","author":"Wajnsztajn","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R21-20250723","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s10792-021-01908-9","article-title":"Risk factors for progression following corneal collagen crosslinking in keratoconus","volume":"41","author":"Sa\u011fl\u0131k","year":"2021","journal-title":"Int Ophthalmol"},{"key":"R22-20250723","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/ojo.OJO_232_2014","article-title":"Long-term use of 0.003% tacrolimus suspension for treatment of vernal keratoconjunctivitis","volume":"10","author":"Al-Amri","year":"2017","journal-title":"Oman J Ophthalmol"},{"key":"R23-20250723","first-page":"NC05","article-title":"Therapeutic effect of 0.1% tacrolimus eye ointment in allergic ocular diseases","volume":"10","author":"Barot","year":"2016","journal-title":"J Clin Diagn Res"},{"key":"R24-20250723","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/ICO.0b013e3181ca3668","article-title":"Meibomian gland duct distortion in patients with perennial allergic conjunctivitis","volume":"29","author":"Arita","year":"2010","journal-title":"Cornea"},{"key":"R25-20250723","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2332\/allergolint.11-OA-0349","article-title":"Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension","volume":"61","author":"Ebihara","year":"2012","journal-title":"Allergol Int"},{"key":"R26-20250723","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/02713680802149115","article-title":"Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study","volume":"33","author":"Attas-Fox","year":"2008","journal-title":"Curr Eye Res"},{"key":"R27-20250723","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: a pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R28-20250723","first-page":"3222","article-title":"Drug delivery to the eye through eyelid skin penetration","volume":"52","author":"Tojo","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20250723","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ijpharm.2017.09.070","article-title":"Eyelid skin as a potential site for drug delivery to conjunctiva and ocular tissues","volume":"533","author":"See","year":"2017","journal-title":"Int J Pharm"},{"key":"R30-20250723","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S32936","article-title":"Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis","volume":"6","author":"Ang","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R31-20250723","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bjophthalmol-2019-313988","article-title":"Steroid-induced glaucoma and blindness in vernal keratoconjunctivitis","volume":"104","author":"Senthil","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R32-20250723","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/s41433-020-1013-y","article-title":"Role of combined immunomodulator therapy in severe steroid intolerant vernal keratoconjunctivitis","volume":"35","author":"Maharana","year":"2021","journal-title":"Eye (Lond)"},{"key":"R33-20250723","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/ejhpharm-2020-002447","article-title":"Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials","volume":"29","author":"Zhao","year":"2022","journal-title":"Eur J Hosp Pharm"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T14:02:28Z","timestamp":1753279348000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000003404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,3]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000003404","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,3]]},"assertion":[{"value":"2023-06-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}